Item(by='refurb', descendants=None, kids=[25923918], score=None, time=1611713405, title=None, item_type='comment', url=None, parent=25922679, text='This is not a bad back of the envelope analysis.  Forbes did one a while back that looked at 10 year R&amp;D spend and then 10 year approvals (to account for the delay).  Numbers vary wildly between companies.<p>But one thing to keep in mind is using your number, there are plenty of drugs that get approved that only have a few billion in sales over their lifetime.  So either break even or not even breaking even.  Itâ€™s a massive blockbusters like Lipitor ($10B in sales per year) that pays for all the mediocre drugs.')